Brief: AB Science/Masitinib: U.S FDA Authorizes Start Confirmatory Phase 3 Study In Treatment Of Alzheimer's
21/11/2022 17:12
Nov 21 (Reuters) - Ab Science Sa ABS.PA :
* AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION
(FDA)
AUTHORIZATION TO INITIATE CONFIRMATORY PHASE 3 CLINICAL STUDY
WITH MASITINIB IN THE TREATMENT OF ALZHEIMER’S DISEASE
* STUDY WILL ENROLL 600 PATIENTS WITH CONFIRMED CLINICAL
DIAGNOSIS
OF MILD AND MODERATE ALZHEIMER'S DISEASE
* OBJECTIVE OF STUDY AB21004 IS TO CONFIRM RESULTS FROM
FIRST
PHASE 2B/3 STUDY, AB09004
Source text for Eikon: ID:nGNX1hjvq
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease